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Christopher R. Helps,a Regina Hofmann-Lehmann,b,d Séverine Taskera
School of Veterinary Sciences, University of Bristol, Bristol, United Kingdoma; Clinical Laboratory,b Clinic for Small Animal Internal Medicine,c and Center for Clinical
Studies,d Vetsuisse Facility, University of Zurich, Zurich, Switzerland
Hemoplasmas are potentially zoonotic mycoplasmal pathogens, which are not consistently cleared by antibiotic therapy.Myco-
plasma haemofelis is the most pathogenic feline hemoplasma species. The aim of this study was to determine how cats previously
infected withM. haemofelis that had recovered reacted when rechallenged withM. haemofelis and to characterize the immune
response following de novo M. haemofelis infection and rechallenge. Five specific-pathogen-free (SPF)-derived naive cats (group
A) and five cats that had recovered fromM. haemofelis infection (group B) were inoculated subcutaneously withM. haemofelis.
BloodM. haemofelis loads were measured by quantitative PCR (qPCR), antibody response to heat shock protein 70 (DnaK) by
enzyme-linked immunosorbent assay (ELISA), blood lymphocyte cell subtypes by flow cytometry, and cytokine mRNA levels by
quantitative reverse transcriptase PCR. Group A cats all became infected with high bacterial loads and seroconverted, while
group B cats were protected from reinfection, thus providing the unique opportunity to study the immunological parameters
associated with this protective immune response againstM. haemofelis. First, a strong humoral response to DnaK was only ob-
served in group A, demonstrating that an antibody response to DnaK is not important for protective immunity. Second, proin-
flammatory cytokine interleukin-6 (IL-6) mRNA levels appeared to increase rapidly postinoculation in group B, indicating a pos-
sible role in protective immunity. Third, an increase in IL-12p35 and -p40 mRNA and decrease in the Th2/Th1 ratio observed in
group A suggest that a Th1-type response is important in primary infection. This is the first study to demonstrate protective im-
munity againstM. haemofelis reinfection, and it provides important information for potential future hemoplasma vaccine
design.
The hemotropic mycoplasmas (hemoplasmas) are a group ofmycoplasmal pathogens that adhere to the surface of red blood
cells (RBCs) and are capable of inducing severe anemia (1). Three
species of hemoplasma are recognized to infect both wild and
domestic cats, with the occasional report of a fourth species (2).
Mycoplasma haemofelis is recognized to be the most pathogenic
species. Acute infection with M. haemofelis can result in severe
hemolytic anemia, demonstrated in some experimental and nat-
ural infections by packed cell volumes (PCVs) falling below 15%
(3, 4), leading to the onset of clinical signs, including pallor, leth-
argy, depression, pyrexia, anorexia, splenomegaly, and lymphade-
nopathy (3, 5, 6); without correct treatment, infection may result
in death (7).
While antibiotics often help alleviate clinical signs, they are not
always successful in clearing the infection (8–10). This can result
in cats developing into chronic carriers, which remain persistently
PCR positive at a low level in the absence of clinical signs of infec-
tion (11). Reactivation of infection remains a possible threat in
chronic carriers (6), and repeated parasitemia in immunosup-
pressed animals has been reported (11). Recently a number of
papers have documented the presence of hemoplasma infections,
including the finding of a short sequence of DNA with 99% iden-
tity to a feline hemoplasma, in humans (12–16). Those in close
contact with domesticated animals, such as veterinarians and
farmers, and those in poor sanitary conditions are reported to be
at an increased risk of hemoplasma infection (14). The failure of
antibiotics to consistently clear these potentially zoonotic patho-
gens highlights the need to investigate the development of any
protective immunity against these bacterial infections. The con-
cept of protective immunity to M. haemofelis is one that has not
been explored.
The aim of this study was to determine whether cats that have
recovered from M. haemofelis infection are protected from rein-
fection with M. haemofelis and to describe the immunological
changes during de novo infection and following rechallenge. All
cats in this study were inoculated using the low-dose subcutane-
ous model developed by Baumann et al. (17), since it is considered
to best mirror the proposed route of “natural infection” by arthro-
pods or aggressive contact between cats (17).
MATERIALS AND METHODS
Animals, experimental design, and hematocrit. Ten specific-pathogen-
free (SPF)-derived male neutered domestic shorthaired (DSH) cats were
used in this study. Group A comprised 5 M. haemofelis-naive cats (HBU2,
HBV1, HCC2, HCD2, and HBZ2 [all 7 months old]), and group B com-
prised 5 cats (AKL4 and ZKA2 [7 years old] and KCU1, KCY2, and JCT2
[4 years old]) that had been previously experimentally infected with M.
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haemofelis (17) and allowed to recover. Four of the 5 group B cats (AKL4,
ZKA2, KCU1, and JCT2) had required 10 mg/kg body weight/day oral
doxycycline for up to 64 days, and 2 cats (AKL4 and KCU1) required 2
mg/kg body weight/day oral marbofloxacin for 13 days in conjunction
with doxycycline, to become M. haemofelis negative by quantitative PCR
(qPCR). Cat KCY2 became M. haemofelis qPCR negative naturally, with-
out antibiotic treatment. All cats in group B were M. haemofelis qPCR
negative on weekly sampling for a minimum of 7 weeks after antibiotic
treatment had stopped before the start of the study. Groups A and B were
housed separately throughout the study.
All 10 cats were inoculated on day 0 subcutaneously in the neck with
100l of dimethyl sulfoxide (DSMO) (20% [vol/vol]) preserved heparin-
ized blood, containing approximately 103 copies of M. haemofelis, diluted
in sterile phosphate-buffered saline (PBS), as previously described (17).
Rechallenge of the group B cats occurred 671 days after the initial inocu-
lation of M. haemofelis.
Blood was collected into EDTA from all cats preinoculation on days
14, 7, and 0 and then postinoculation (p.i.) on days 1, 2, and 3, fol-
lowed by once-weekly blood collections (on days 10, 17, 24, 31, 38, 45, 49,
56, 63, 70, 77, and 84 p.i.) up to day 84 p.i. for M. haemofelis qPCR,
serology, cytokine analysis, hematocrit (HCT), and flow cytometry. Ad-
ditionally blood was collected midweek (on days 6, 13, 21, 28, 35, and 42
p.i.) for hematocrit, M. haemofelis qPCR, and serology only.
Hemograms were run on a Sysmex XT-2000iv (Sysmex Corporation,
Kobe, Japan) validated for cat blood samples (18). The reference range for
hematocrit (HCT) was previously determined to be 33 to 45% (19). Cats
were considered anemic if HCT was below 33%.
This study was approved by both the University of Bristol’s Ethical
Review Group (UB/12/021) and the Veterinary Office of the Canton Zu-
rich, Switzerland (TVB 159/2010). The cats were kept in groups under
ethologically and hygienically ideal conditions, as described previously
(20).
TNA extraction. Total nucleic acid (TNA) was extracted using the
MagNa Pure LC total nucleic acid isolation kit (Roche Diagnostics, Rot-
kreuz, Switzerland) from 100 l of EDTA blood diluted in 100 l of PBS.
An extraction control of 200l of PBS was included with every extraction
run to detect any cross contamination.
Feline albumin gene internal control qPCR. All samples were sub-
jected to a feline albumin qPCR assay to confirm the presence of DNA
within each sample (21). Those that contained less than 103 copies of
feline albumin underwent repeat extraction of a second sample and were
again subjected to feline albumin qPCR. If repeat analysis failed to dem-
onstrate adequate copies of feline albumin, the sample was not subjected
to M. haemofelis qPCR.
Mycoplasma haemofelis qPCR. Total nucleic acid from each sample
was screened for the presence and quantity of M. haemofelis DNA via an
M. haemofelis-specific TaqMan qPCR, as described previously (5). In or-
der to scale up the reaction for the number of copies of M. haemofelis
present per ml of blood, the results of the qPCR were multiplied by 200,
taking into account the volume of blood extracted, the volume of elution
buffer that the DNA was eluted into, and the volume of DNA added to the
PCR assay mixture, assuming 100% efficiency.
Flow cytometry. B220 cells, identified B cells, and CD4 and CD8
cells were analyzed to identify the helper and cytotoxic T cells, respec-
tively. CD4CD25 and CD5major histocompatibility complex class II
(MHC-II) cells were used for markers of activated T cells. These staining
combinations have all been used previously for feline research (19).
Fifty microliters of EDTA-treated blood was incubated with 5 l of 1
of 3 different staining combinations of primary antibody: (i) fluorescein
isothiocyanate (FITC)-conjugated mouse anti-feline CD25 antibody
(kindly provided by G. Dean, Colorado State University) and R-phyco-
erythrin (RPE) mouse anti-feline CD4 (AbDserotec, MorphoSysAbD
GmbH, Germany), (ii) FITC-conjugated mouse anti-feline CD5 (F43;
Southern Biotech) and unconjugated IgG2b mouse anti-feline MHC-II
(H34A; VMRD), or (iii) unconjugated IgG1 mouse anti-feline CD8 (FT2;
Southern Biotech) and peridinin chlorophyll a protein (PerCP)-conju-
gated rat anti-mouse B220 (RA3-6B2; BD Bioscience).
Blood samples from each cat were used as isotype-matched control
antibody and unstained negative controls. For those combinations of an-
tibodies requiring secondary antibodies (combinations 2 and 3), only the
primary antibody within the combination that required the addition of a
secondary antibody (MHC-II [combination 2] and CD8 [combination
3]) was added in the first incubation step to prevent nonspecific binding.
After incubation, 500 l of VersaLyse (Beckman Coulter, Nyon, Switzer-
land) erythrocyte lysing solution was added to each sample tube, and the
sample was vortexed and incubated in the dark at room temperature for
10 min. After complete erythrocyte lysis, each tube was centrifuged at
600 g for 5 min to form a pellet of leukocytes, and the supernatant was
discarded. The pellet was incubated with 50 l of secondary antibody
(RPE-labeled goat anti-mouse IgG2b [Southern Biotech, Birmingham,
AL]) for the unlabeled anti-MHC-II antibody and allophycocyanin
(APC)-labeled rat anti-mouse IgG1 (BD Pharmingen) for the unlabeled
anti CD8 antibody or PBS containing 1% fetal calf serum (FCS) for 20 min
in the dark. After incubation, the cells were washed in PBS containing 1%
FCS and centrifuged at 1,200  g for 5 min, and the supernatant was
discarded. Those staining combinations that required a secondary anti-
body (combinations 2 and 3) then had 5 l of their other primary anti-
body (CD5 [combination 2] and B220 [combination 3]) added at this
point and were incubated in the dark for 30 min, followed by washing of
the cells in PBS containing 1% FCS and centrifugation at 1,200 g for 5
min. Leukocyte pellets were resuspended in 250 l of PBS–1% FCS. Flow
cytometry was performed on a Guava easyCyte HT sampling flow cytom-
eter (Millipore Corporation, Billerica, MA) using the InCyte software.
Gates were set using forward and reverse scatter for the lymphocyte pop-
ulation, and up to 10,000 events were acquired for each sample.
The absolute number of each lymphocyte cell subset was calculated as
described previously (22), and to “correct” for differences in lymphocyte
number between the two groups preinoculation, the results were ex-
pressed as the percentage change from preinoculation for each lympho-
cyte cell subset at each time point.
Serology. A recombinant M. haemofelis heat shock protein 70 (DnaK)
enzyme-linked immunosorbent assay (ELISA) modified after that de-
scribed by Barker et al. (23) was used, with ELISA plates (Thermo Scien-
tific 96-well, vinyl, flat-bottom microtiter plates) coated with 100 l of a
1:2,500 dilution of recombinant DnaK (rDnaK) synthesized by Barker et
al. (23). Plasma samples were serially diluted 3-fold, from a 1:3 dilution to
a 1:6,561 dilution, and each plate included a duplicated positive standard
from Barker et al. (23). A 1:5,000 dilution of alkaline phosphatase-conju-
gated goat anti-cat IgG Fc (Jackson immunoresearch) secondary antibody
(diluted 50% [vol/vol] in glycerol) was used in this study. Following the
addition of the detection substrate, plates were incubated in the dark for
60 min, after which the optical densities at 405 and 492 nm (OD405 and
OD492, respectively) were measured using a computer-assisted ELISA
plate reader (Labsystems Multiskan EX Primary EIA v2.1-0 with Genesis
v3.0; VWR International, Ltd., Lutterworth, United Kingdom).
Samples were analyzed by plotting the log of their optical density (OD)
against the log concentration of the sample. The relative antibody level
(RAL) was calculated by comparison with the standard dilution series,
where the undiluted standard was given an RAL of 1,000. The mean of the
results from each sample’s dilutions was calculated to give the RAL. Cats
were identified as having seroconverted when their RAL crossed the
threshold of seropositivity, calculated as the mean of the preinoculation
RALs for all cats in group A plus 3 standard deviations (SD) (23). Optical
density readings of all dilutions at several time points from one cat in
group B and some early time points of some individual cats in group A
were just off the standard curve; these levels were seen to represent very
low levels of antibody and for statistical analysis were represented by 0.
mRNA extraction and cDNA synthesis. One hundred microliters of
EDTA-blood was mixed with 300 l of mRNA isolation lysis buffer
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(mRNA isolation kit I; Roche Diagnostics) directly after blood collection
and stored at80°C until mRNA isolation was performed.
The isolation of mRNA was carried out using the MagNA Pure LC
mRNA HS kit (Roche Diagnostics) according to the manufacturer’s in-
structions. An extraction control of 100l of PBS was run alongside every
batch extraction to detect any cross contamination. The mRNA was
eluted in 25l of elution buffer and stored at80°C until cDNA synthesis
could be performed.
For each mRNA sample, two reverse transcription reactions were per-
formed using the high-capacity cDNA reverse transcription kit from Ap-
plied Biosystems following the manufacturer’s instructions and then the
products were pooled and stored at20°C until use.
CytokinemRNAanalysis.Relative levels of interleukin-4 (IL-4), IL-6,
IL-10, IL-12p35, IL-12p40, gamma interferon (IFN-), and tumor necro-
sis factor alpha (TNF-) mRNA were determined by qPCR. IL-12p35,
IL-12p40, and IFN- were chosen as Th1 cytokines to determine if re-
sponses postinoculation were directed to a Th1 response. Conversely IL-4
and IL-10 were chosen as Th2 cytokines. IL-6 and TNF-were analyzed to
detect any proinflammatory response. IL-12p35 and IL-12p40 mRNA
levels were determined separately as IL-12 is encoded by 2 separate genes,
p35 and p40, which are situated on separate chromosomes and indepen-
dently expressed (24).
The primers and probes had been designed previously (25), and these
reactions were optimized for use on an Mx3005P qPCR system (Agilent,
Berkshire, United Kingdom). Each PCR mixture consisted of 6.25 l of
GoTaq Hot Start polymerase (Promega, Southampton, United King-
dom), MgCl2 to a final concentration of 4.5 mM, forward and reverse
primers at a concentration of 200 nM, probe at a concentration of 100 nM,
2.5 l of DNA template, and water to a final volume of 12.5 l. For each
96-well plate, 3 positive controls (of known threshold cycle [CT] values)
and 3 negative water controls were also run.
The qPCRs were carried out on an MX3005P qPCR system. Incuba-
tion at 95°C for 2 min was followed by 45 cycles of 95°C for 15 s and then
60°C for 30 s for V-abl Abelson murine leukemia viral oncogene (ABL),
zeta polypeptide (YWHAZ), IL-4, IL-12p35, IL-12p40, and TNF- assays
or 58°C for 30 s for IL-6, IL-10, and IFN- assays. Assays were run in
duplicate for each cDNA sample.
The ABL and YWHAZ assays amplified the mRNA of two housekeep-
ing genes, and all assays were normalized to these two housekeeping genes
(19) using an adaption of the method used by Taglinger et al. (25). For
each housekeeper (HK), a correction value was calculated using the for-
mula HK correction value a constant numbermean CT of the house-
keeper. The correction value was then added to each result from the dif-
ferent cytokine assays: corrected CT CT target  HK correction value.
The relative copy number was determined by the calculation relative copy
number efficiency	CT, where 	CT 45 corrected CT.
The mean of the 2 replicates of each cytokine mRNA was then calcu-
lated, followed by the averaging of the sets of normalized data from the 2
housekeepers for each cytokine.
To allow for differences in cytokine expression levels between the two
groups at preinoculation, the percentage of change in cytokine mRNA
expression levels postinoculation relative to preinoculation was calculated
for each time point.
Following initial cytokine mRNA expression analysis, the ratios of
IL-4 to IL-12p35 mRNA, IL-4 to IL-12p40 mRNA, and IL-4 to IFN-
mRNA were calculated as indicators of Th2/Th1 ratios, as used previously
(19).
Statistical analysis. The statistical software package IBM SPSS Statis-
tics version 19 was used to perform statistical analysis. The data were not
amenable to parametric testing, so we were unable to fit a model to the
whole data. Mann-Whitney U tests (PMWU values) were used to make
comparisons between both groups at each time point for each dependent
variable. Friedman’s tests (PFriedman values) were used to determine if
there was a statistically significant change over time for each group, fol-
lowed by the Wilcoxon signed rank test (PWilcoxon values) to determine
where any change from preinoculation was significant. Significance was
taken at P 
 0.05. Difficulties exist in assessing the level of correction
required for these multiple comparisons, as some correlation exists
between the measurements at different time points. Thus, we have
reported P values that are uncorrected for multiple comparisons and
present these results as a general guide to identify where differences are
likely to occur.
RESULTS
Rechallenged cats demonstrate protection againstM. haemofe-
lis infection. All cats in group A (de novo infection) became M.
haemofelis qPCR positive by day 21 p.i., with mean peak bactere-
mia reaching 5.79 108 copies/ml blood at 24 days p.i. (Fig. 1A).
A clear cycling of M. haemofelis copy numbers was observed
(Fig. 1A).
In contrast, no evidence consistent with sustained multiplica-
tion of M. haemofelis was observed in group B (Fig. 1B). Three of
the cats in group B (rechallenged with M. haemofelis: KCU1,
KCY2, and JCT2) each gave just one positive M. haemofelis qPCR
result, while cat ZKA2 (Fig. 1B) gave 2 positive results during the
study; these low-level qPCR results showed M. haemofelis loads of
FIG 1 M. haemofelis copy numbers per ml of blood and hematocrit results
during this study for groups A (A) and B (B). M. haemofelis copy numbers are
reported as log values. All cats in group A became M. haemofelis PCR positive
after inoculation by 21 days p.i., whereas the cats in group B remained PCR
negative for the vast majority of the time, with only rare very low positive
values recorded. Clear cycling was observed in the cats in group A: e.g., cat
HCC2 showed a 4-log increase from day 21 to day 24 p.i., followed by a 4-log
decline from day 24 to day 28 p.i. Dashed lines indicate hematocrit values.
Hicks et al.
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only 265 copies/ml of blood or less (Fig. 1B). These low-level pos-
itive results were only just above the level of detection of the PCR
assay, which is deemed to be 1 copy per PCR (thus equivalent to
200 copies per ml of blood). The results are suggestive of protec-
tion against M. haemofelis infection in the group B cats, as they
indicate group B’s ability to control the bacteremia, with no signs
of bacterial levels rising further above the PCR detection limit.
Each time point that gave a negativeM. haemofelis qPCR result for
group B was retested in duplicate to check for any low-level posi-
tive result; none were detected. The negative PCR status of the cats
following identification of these very low levels is indicative of
protection against M. haemofelis.
All cats in group A became anemic during the study (Fig. 1A),
although this was mild. The lowest HCT recorded was 20% on day
38 p.i. (HCD2). The HCTs for group B all remained within the
reference range (Fig. 1B).
Naive infection is characterized by a reduction followed by a
proliferation in lymphocyte cell subset numbers. In group A, all
cell subsets showed a significant difference over time (PFriedman
0.001) (Table 1), with a number of different cell subsets following
a similar pattern: B220, CD8, CD4, and CD5MHC-II (Fig.
2A to D). There was a significant decrease (PWilcoxon
 0.05) from
preinoculation cell numbers at various time points early (up to
around day 31 p.i.) in the study period (Table 1), with the nadir
TABLE 1 Statistical analysis of each test variable for the two groups in this study
Test variable
Cat
group
Statistical analysis for any significant difference
in variable over time (PFriedman value)
Day(s) p.i. with significant differences
(PWilcoxon*) from preinoculation levels
a
M. haemofelis rDnaK ELISA A 2  82.859 (
0.001) 24, 28, 31, 35, 38, 42, 45, 49, 56, 63, 70, 77, 84
B NSb Not performed
IL-12p35 mRNA A 2  51.741 (
0.001) 24, 31, 38, 45, 49, 84
B 2  31.624 (0.007) 17, 31, 45, 49
IL-12p40 mRNA A 2  35.082 (0.002) 1, 3, 10, 24, 31, 38, 45
B NS Not performed
IFN-mRNA A NS Not performed
B NS Not performed
IL-4 mRNA A 2  35.100 (0.002) 2, 63, 84
B 2  26.382 (0.034) 24, 31, 77
IL-10 mRNA A 2  52.094 (
0.001) 17, 24, 31, 38, 45, 56, 63, 70
B 2  27.159 (0.027) 56
IL-6 mRNA A NS Not performed
B NS Not performed
TNF-mRNA A 2  28.200 (0.020)
B 2  29.382 (0.014) 24, 49, 84
IL-4/IL-12p35 mRNA A 2  48.371 (
0.001) 31, 38, 45, 49, 63, 70, 84
B 2  34.2 (0.003) 49, 56, 77
IL-4/IFN-mRNA A 2  29.576 (0.014) 56, 63, 70
B 2  25.129 (0.048) 63
B220 A 2  54.706 (
0.001) 3, 24, 31, 63, 70, 77, 84
B 2  31.624 (0.007) 77, 84
CD8 A 2  49.288 (
0.001) 24, 63, 70, 77
B 2  30.476 (0.010)
CD4 A 2  46.271 (
0.001) 24, 31, 38, 45
B NS Not performed
CD4 CD25 A 2  36.918 (0.001) 49, 70, 77, 84
B 2  28.588 (0.018) 38, 45, 70, 84
CD5 MHC-II A 2  49.624 (
0.001) 24, 38, 45, 63, 70, 77
B NS Not performed
a Blood samples for cytokines and flow cytometry were collected on days 1, 2, 3, 10, 17, 24, 31, 38, 45, 49, 56, 63, 70, 77, and 84 p.i. Only those values that were significant at
PFriedman 
 0.05 were subjected to the Wilcoxon signed-rank test. * indicates z2.023 and PWilcoxon  0.043. Numbers in boldface indicate a significant increase in comparison
to preinoculation levels, while numbers not in boldface indicate a significant decrease in comparison to preinoculation levels.
b NS, no significant difference.
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reached at day 24 p.i. (Fig. 2A to D); an increase in cell numbers
then occurred (Fig. 2A to D), which corresponded with the time
when antibody and cytokine levels increased dramatically in
group A, such that significant increases (PWilcoxon 
 0.05) from
preinoculation numbers were seen at various time points toward
the end of the study (Table 1). The numbers of CD4CD25 cells
in group A showed a similar but more varied cyclical pattern (Fig.
2E) and were significantly increased (PWilcoxon 
 0.05) from pre-
inoculation numbers on day 49 p.i. and toward the end of the
study (Table 1).
Significant differences over time were identified in group B for the
B220, CD8(PFriedman  0.01), and CD4
 CD25 (PFriedman 

0.05) cell subsets, whereas CD4 and CD5 MHC-II cells did not
differ over time (Table 1). In contrast with group A, the fluctuations
in B220, CD8, and CD4 CD25 cell numbers were not marked
in group B (Fig. 2A, B, and E), and fewer significant differences com-
pared to preinoculation numbers were seen (Table 1).
Some significant differences (PMWU 
 0.05) in cell subsets
were seen between groups A and B at various time points p.i. (Fig.
2); generally group A had lower levels of most of the cell subsets
around day 24 p.i. but then had higher levels later in the study,
around days 77 to 84 p.i.
Protective immunity is not associatedwith a secondary anti-
body response to rDnaK. Cats in group A seroconverted, on av-
erage, 21 days p.i. (Fig. 3). Relative antibody levels were increased
significantly (PWilcoxon 
 0.05) on day 24 p.i. compared to prein-
oculation and remained significantly (PWilcoxon 
 0.05) higher
throughout the remainder of the study (Table 1), with a maximal
mean RAL reached on day 31 p.i. (Fig. 3). No significant changes
in RAL in group B occurred over time (Table 1 and Fig. 3).
From day 31 p.i., levels of rDnaK antibodies were significantly
(PMWU 
 0.05) greater in group A than those of group B and
remained so for most of the remaining time points of the study
(Fig. 3).
Increased levels of both IL-12 mRNA subunits indicate a
Th1-type response following naive infection. Levels of IL-12p35
mRNA in group A varied significantly (PFriedman 
 0.001) over
time (Table 1), with levels being significantly (PWilcoxon 
 0.05)
higher than those at preinoculation midway through the study
between days 24 and 49 p.i. (Table 1), reaching a peak on day 45
p.i. (Fig. 4A). Changes in IL-12p35 mRNA levels in group B largely
mirrored those of group A (Fig. 4A), although levels were signifi-
cantly higher (PWilcoxon 
 0.05) than those at preinoculation at
fewer time points (Table 1). No significant differences in IL-12p35
mRNA levels were found between groups A and B (Fig. 4A).
Levels of IL-12p40 mRNA in group A varied significantly
(PFriedman 
 0.01) over time (Table 1), with levels being signifi-
cantly (PWilcoxon 
 0.05) higher than preinoculation levels both
FIG 2 Percentage of change from preinoculation with B220 (A), CD8(B), CD4 (C), CD5MHC-II (D), and CD4CD25 (E) cells over the course of the
experiment for groups A () and B (Œ). Each value represents the mean result for the group, and error bars represent the standard error. Time point 0 represents
the preinoculation value (mean from time points14,7, and 0). *, statistically significant difference between the two groups at PMWU 
 0.05.
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early (days 1, 3, and 10 p.i.) and midway (days 24 to 45 p.i., when
a double peak occurred) (Fig. 4B) through the study period. In
contrast there were no significant differences in IL-12p40 mRNA
levels over time for group B (Table 1). IL-12p40 mRNA levels were
significantly (PMWU 
 0.05) greater in group A than those in
group B on day 3 p.i. only (Fig. 4B). No significant differences in
IFN-mRNA levels over time were detected for either group A or
B (Table 1). However, group A had significantly (PMWU 
 0.05)
higher IFN-mRNA levels than group B on days 2, 24, 56 (PMWU

0.01), and 70 p.i. (Fig. 4C).
Significant increases from preinoculation in both subunits of
IL-12 mRNA for group A suggest that a Th1-type response occurs
following naive infection.
IL-10 mRNA expression appears to show a Th2-type re-
sponse in naive infection but not protective immunity. IL-4
mRNA levels in group A were transiently significantly increased
FIG 3 The humoral response to an rDnaK protein. Each value represents the mean log-transformed relative antibody level (RAL) for the group of cats, and error
bars indicate the standard error. Time point 0 represents the preinfection value (mean RALs from time points 14, 7, and 0). *, statistically significant
difference between the two groups at PMWU 
 0.05. The threshold represents seropositive status in group A de novo-infected cats.
FIG4 Percentage of change from preinoculation of Th1-type cytokines IL-12-p35 (A), IL-12p40 (B), and IFN- (C) over the course of the experiment for groups
A () and B (Œ). Each value represents the mean result for the group, and error bars represent the standard error. Time point 0 represents the preinoculation
value (mean from time points14,7, and 0). *, statistically significant difference between the two groups at PMWU 
 0.05; **, significance at PMWU 
 0.01.
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on day 2 p.i. (PWilcoxon 
 0.05) (Table 1) but quickly fell back to
preinfection levels before increasing, nonsignificantly, up to 24
days p.i. (Fig. 5A). The levels subsequently fell and were signifi-
cantly (PWilcoxon 
 0.05) decreased in comparison to preinocula-
tion levels at the end of the study (Table 1 and Fig. 5A). The general
pattern of IL-4 mRNA expression was similar in group B, although
increases from preinoculation levels were significant at days 24 and 31
p.i. (PWilcoxon 
 0.05) (Table 1). No significant differences were de-
tected at any time point between groups A and B.
There was a significant (PFriedman 
 0.001) change in the level
of IL-10 mRNA over time for group A, with levels significantly
(PWilcoxon 
 0.05) greater than those preinoculation on most p.i.
sampling days between days 17 and 70 (Table 1), reaching a peak on
day 31 p.i. (Fig. 5B). Group B also showed significant (PFriedman 

0.05) differences in IL-10 mRNA levels over time (Table 1), but only
levels at day 56 p.i. were significantly (PWilcoxon
 0.05) different and
were decreased compared to preinoculation levels (Table 1). Levels of
IL-10 mRNA were significantly (PMWU
 0.05) increased in group A
compared to group B from day 17 until day 70 p.i. (Fig. 5B). These
results indicate a possible role of a Th2-type response in group A cats,
in accordance with the production of antibodies against rDnaK.
Potential role of proinflammatory cytokines in protective
immunity. There was a high level of variation of IL-6 mRNA
between cats, and no statistically significant differences in levels
over time were found either within (Table 1) or between (Fig. 6A)
groups A and B. However, group IL-6 mRNA expression levels
were (nonsignificantly) increased above preinoculation levels on 4
consecutive sampling days up to 17 days p.i. in group B, a se-
quence that was not observed in group A (Fig. 6A), suggesting a
possible role of this cytokine in protective immunity.
Levels of TNF-mRNA showed a significant (PFriedman
 0.05)
difference over time in group A (Table 1), but with no clear pat-
tern for changes in expression (Fig. 6B) seen, and at no sampling
point p.i. were levels significantly different from preinfection lev-
els (Table 1). Group B also showed a significant (PFriedman
 0.05)
difference over time in TNF- mRNA levels (Table 1), with sig-
nificant (PWilcoxon 
 0.05) peaks in expression on days 24 and 49
p.i. (Fig. 6B), corresponding to time points at which the levels
of TNF- mRNA in group B were significantly (PMWU 
 0.05)
greater than those in group A (Fig. 6B). However, levels declined
after each of these peaks, approximating preinfection levels.
Decrease in Th2/Th1 ratios occurred in both naive infection
and protective immunity. The IL-4/IL-12p35 mRNA ratios showed
a significant difference over time in both groups A (PFriedman
0.001)
and B (PFriedman
 0.01) (Table 1), with significant (PWilcoxon
 0.05)
decreases compared to preinoculation levels at various time points
between days 33 and 84 p.i. (Table 1). No significant differences be-
tween groups A and B were found at any time point (Fig. 7A). A
similar pattern of expression was observed for the IL-4/IL-12p40
mRNA ratios (data not shown). The IL-4/IFN- mRNA ratios
showed a significant (PFriedman 
 0.05) difference over time in both
groups A and B (Table 1), with significant (PWilcoxon
 0.05) differ-
ences found compared to preinoculation levels toward the end of the
study (Table 1), although no significant differences between groups A
and B were found at any time point (Fig. 7B).
DISCUSSION
While low, intermittent levels of bacteria, just above the detection
limit of the PCR assay, were detected in 4 of 5 cats in group B, the
absence of continued bacterial multiplication and the PCR-nega-
FIG 5 Percentage of change from preinoculation of Th2-type cytokines IL-4
(A) and IL-10 (B) over the course of the experiment for groups A () and B
(Œ). Each value represents the mean result for the group, and error bars rep-
resent the standard error. Time point 0 represents the preinoculation value
(mean from time points14,7, and 0). *, statistically significant difference
between the two groups at PMWU 
 0.05; **, significance at PMWU
 0.01.
FIG 6 Percentage of change from preinoculation of proinflammatory cyto-
kines IL-6 (A), and TNF- (B) over the course of the experiment for groups A
() and B (Œ). Each value represents the mean result for the group, and error
bars represent the standard error. Time point 0 represents the preinoculation
value (mean from time points14,7, and 0). *, statistically significant dif-
ference between the two groups at PMWU 
 0.05.
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tive status thereafter are evidence of protection against M. hae-
mofelis reinfection. These cats showed very occasional positive
results by qPCR (in only 5 of the 105 p.i. samples from group B:
once each for KCU1, KCY2, and JCT2 and twice for ZKA2). These
low-level positive results were not thought indicative of sustained
infection as there was no evidence of multiplication of M. hae-
mofelis from levels just above the qPCR assay’s limit of detection.
These results represent levels that were very much lower (by107-
fold) than those of the cats in group A, where the M. haemofelis
loads showed continued sustained bacterial multiplication. Thus,
we believe this study demonstrates, for the first time, protection
from infection after an M. haemofelis rechallenge.
It is possible that the occasional positive qPCR results recorded
in group B, just above the detection limit of the qPCR, represented
laboratory contamination, but all qPCR-negative controls were
appropriately negative in every PCR run, making this unlikely.
Alternatively, these positive results could reflectM.haemofelis car-
rier cat status, but no positive qPCR results were seen in the time
period (minimum 7 weeks) between cessation of antibiotic treat-
ment and the start of the study (data not shown). We might also
have expected to have seen many more than 5 M. haemofelis-
positive PCR results in the group B cats were these true carrier
cats. Additional qPCRs performed on each group B cat at its neg-
ative qPCR time points failed to yield any positive results, al-
though it is possible that the identification of chronic carrier cats
in group B may have been limited by the times when the cats were
sampled. However, it is important to note that whether or not the
cats in group B were chronically infected, they were still protected
from succumbing to a rechallenge infection, as evidenced by the
difference in results in group A compared to group B. We could
have immunosuppressed the cats in group B before rechallenge to
determine if carrier status existed by reactivation of the initial
infection, as has been reported previously (11). However, time
and ethical restraints meant that this was not possible during this
study. An alternative explanation for the odd low-level PCR re-
sults could be that the bacteria used to inoculate the cats were
being detected but were prevented from multiplying, although
one might have expected the positive qPCR results to have been
detected earlier than they were found. A control group consisting
of 5 cats infected with hemoplasma-free blood in 20% DMSO
would have been ideal to use as a comparison to the de novo and
rechallenged cats. However, cost limitations precluded this in the
present study, and previous studies have similarly not included
such control cats (3, 17, 19).
In contrast, all cats in group A developed a high bacteremia and
the characteristic cyclical nature of M. haemofelis bacterial loads,
as previously described (8, 10, 17). There was a difference in age
between the two groups of cats in this study, with group A com-
prising younger cats, and it is possible that this difference could
have influenced the outcomes following inoculation with M. hae-
mofelis. However, the older cats (group B) were first challenged
with M. haemofelis at the ages of 3 and 6 years, and this had re-
sulted in all cats becoming infected, with anemia developing in 4
out of the 5 cats (17); therefore, we would have expected similar
results following rechallenge in this study. Previously, clinical
signs of disease have usually developed at the time of the highest
bacterial loads (3, 8, 11), but in the present study, all group A cats
became only mildly anemic, showing drops in their hematocrit
but no outward signs of clinical illness (data not shown), despite
the known pathogenicity of this organism, illustrating that clinical
signs do not necessarily indicate infection status. The young age of
the cats in group A is unlikely to explain their lack of clinical signs
as a previous study that involved experimentally infecting
7-month-old cats with M. haemofelis resulted in the development
of severe anemia in 8 out of the 10 cats (3). The former studies (3,
8, 11) had used intravenous inoculation, unlike the low-dose sub-
cutaneous inoculation used in the present study, although intra-
venous inoculation of M. haemofelis is not always associated with
severe disease (8, 26). The subcutaneous method may more accu-
rately mirror the natural route of infection but could be associated
with lower pathogenicity. However, a previous low-dose subcuta-
neous M. haemofelis infection study reported 4 of 5 cats develop-
ing anemia, of which 3 showed signs of clinical illness (17). The
same inoculum was used in this study as in the low-dose model
study; this along with the high parasitemia observed in the group
A cats should indicate that all 10 cats were effectively challenged.
In this study, the aim was to determine whether cats were pro-
tected from infection rather than pathogenicity; therefore, we be-
lieve that the lack of clinical signs observed in the naive infection
does not mean that the challenge was not effective for this study.
No known effective methods for preventing M. haemofelis in-
fection exist, nor are data available regarding the immune re-
sponses that occur following infection, so the findings of the pres-
FIG 7 Ratios of IL-4 to IL-12p35 mRNA (A) and IL-4 to IFN-mRNA (B) in
groups A () and B (Œ) over the course of the study. Mean log-transformed
values are plotted, and error bars represent the standard error.
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ent study documenting prevention of reinfection and associated
immunological changes represent an important advancement in
our understanding of immunity to M. haemofelis infection. No
studies have previously evaluated protection from rechallenge
with this feline hemoplasma species, although a recent study did
evaluate protection from rechallenge with the less pathogenic he-
moplasma species “Candidatus Mycoplasma turicensis,” and ap-
parent protection was reported (19). In pigs, a recombinant
MSG1 (Mycoplasma suis GAPDH [glyceraldehyde-3-phosphate
dehydrogenase]-like protein 1) vaccine failed to induce protective
immunity against the porcine hemoplasmaM. suis, despite induc-
ing a strong immune response characterized by the induction of
both IgG1 and -2 antibodies and the proliferation of splenocytes
(27). Our study, documenting protection from M. haemofelis re-
challenge, suggests that a vaccination approach involving attenu-
ated whole organisms may offer a route to hemoplasma protec-
tion.
All cats in group A seroconverted to rDnaK by 28 days p.i., in
agreement with previous studies (17, 23, 28). Interestingly, despite
the strong humoral response produced during naive infection, the
antibody levels to rDnaK did not rise and remained relatively con-
stant throughout the study in group B cats. This suggests that the
response to rDnaK is not important for protective immunity, but
it may be that these slightly raised, albeit low, and constant levels
of rDnaK antibody seen both preinoculation and p.i. provided
long-lasting protection against M. haemofelis, or there was rapid
clearance of any immune complexes generated. A similar lack of
increase in rDnaK antibody levels was also seen in cats protected
from “Ca. Mycoplasma turicensis” rechallenge following previous
recovery from infection with this organism (19). It may be that
other patterns of antibody production occur for other hemo-
plasma immunogenic determinants (29) that mediate protection,
but testing methods to demonstrate such antibodies are not yet
available.
Effector T cells expressing CD4 can be divided into type 1 and
type 2 helper T cells (Th1 and Th2, respectively). The Th1 and Th2
paradigm is a useful model in which to determine the direction of
the immune response following infections (30), with Th1 gener-
ally governing the clearance of intracellular pathogens, while Th2
controls extracellular pathogens (although cell subsets other than
Th1 and Th2 are also involved). Evidence suggests that this model
may also be of relevance in cats (31). The immunological changes
in group A, as they became M. haemofelis qPCR positive, were
overall suggestive of a Th1-type response. Even though IFN-
levels did not change significantly (although they were signifi-
cantly greater than those in group B at various time points), the
increased mRNA levels of both IL-12p35 and IL-12p40 (and thus
IL-12) p.i. and decreases in the IL-4/IL-12p35 and IL-4/IFN-
mRNA ratios support the presence of a Th1 response in group A.
Analysis of the IL-4/IL-12p35 and IL-4/IFN- mRNA ratios in
group B cats also showed a decrease p.i.; however, in group B only
IL-12p35 and not IL-12p40 mRNA levels increased significantly
p.i. IL-12 is a heterodimer formed of two individually expressed
subunits, p35 and p40 (32), and it is important that both subunits
are analyzed together to determine the IL-12 bioactive expression,
so we cannot conclude that IL-12 protein levels were increased in
group B p.i. Additionally, group B had no changes p.i. in IFN-
mRNA, making it unlikely that they showed a Th1 response.
It has been suggested that the Th2 response can be character-
ized through the production of antibodies and increases in IL-4
and IL-10 mRNA levels. IL-4 mRNA levels were raised in both
groups A and B p.i., but no significant differences between the two
groups occurred. IL-10 mRNA levels were raised p.i. in group A,
and antibodies to rDnaK were also detected in this group, indicat-
ing some Th2 response activity following de novo infection. How-
ever, IL-10 can also be produced by regulatory T cells (Tregs);
therefore, there is also potential of involvement of these cells in the
group A response. IL-10 is an anti-inflammatory cytokine that is
able to inhibit the action of Th1 cells as well as a number of other
cell types involved in the immune response (33). The increased
levels of IL-10 mRNA in group A throughout the study period
suggest a role of this cytokine in limiting the inflammatory re-
sponse to M. haemofelis and potentially preventing the clearance
of the organism, as it has been shown to do for Leishmania major
(34), leading to chronic M. haemofelis infection. The absence of
antibody production and the presence of no increase in IL-10
mRNA levels in group B appear to show that a Th2-type response
is absent following reinoculation. Surprisingly, these results were
in contrast to those from the “Ca. Mycoplasma turicensis” rechal-
lenge study, where the authors proposed that a Th2-type response
p.i. in the protected cats was associated with the protection from
reinfection (19). The reason for this contrast could be due to dif-
ferences in the pathogenicity between the two species (5).
The proinflammatory cytokines TNF- and IL-6 were the only
cytokines in which mRNA levels appeared to increase from prein-
oculation in group B cats predominantly. TNF- has been linked
to the defense against some bacterial infections (35, 36). In this
study, mRNA levels were raised significantly in group B at 2 sep-
arate time points. It might be expected that to confer protection
from reinfection, the changes in the immune response must occur
rapidly p.i. No such rapid significant changes were identified for
any cytokine mRNA tested in the present study, although a non-
significant increase in IL-6 mRNA expression was seen in group B.
IL-6 is a pleiotropic cytokine that induces the generation of IL-17-
producing Th17 cells, a third T helper cell division (37). It is pos-
sible that there is a lack of a skew toward either a Th1 or Th2
response in the group B cats, as IL-6 may be an indicator of a Th17
response, which provides defense against extracellular bacteria, as
well as intracellular bacteria and fungi, via the activation of neu-
trophils (38). In order to define the role of Th17 cells in protective
immunity to M. haemofelis, further studies evaluating the levels of
IL-17 mRNA in rechallenged cats are required.
Our findings indicated that most lymphocyte cell subsets fol-
lowed a similar pattern in group A, characterized by a decrease in
the number of cells at the time of maximal bacteremia in compar-
ison to preinoculation levels, and then an increase until the end of
the study. The decrease is most likely explained by the cells mi-
grating from the peripheral blood to the draining lymph nodes,
where they become activated and proliferate, resulting in the in-
creased levels of immune cells at the end of the study. Proliferation
of the different cell subsets corresponded with the time of strong
antibody production and increased cytokine response in the
group A cats. The only subset in group A that failed to follow this
path were the CD4 CD25 cells, which showed cyclical variabil-
ity. CD25 is a T cell activation marker. The results thus indicate
a cyclic behavior of these activated T cells. When bacterial num-
bers are high, it is likely that the activated T cells are being seques-
tered to a site where they become further activated. In a previous
“Ca. Mycoplasma turicensis” protection study, it was suggested
that the dual expression of CD4 and CD25 might be used as a
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marker of regulatory T cells, which are able to suppress Th1 and
Th2 responses, limiting the immune response to infection to pre-
vent tissue damage and an excessive response (19, 39); however,
CD4 CD25 expression alone is only an indirect marker of reg-
ulatory T cell populations (40); it is now known that Forkhead box
P3 (FOXP3) should also be targeted to determine regulatory sub-
sets (41), but such reagents were not available in this study. Al-
though analysis of the CD4 CD25 data with the IL-10 mRNA
levels suggests that there may be a role of CD4 CD25 FOXP3
IL-10-producing regulatory T cells (42) in the group A cats;
whether these cells exist within the cat is unknown. No changes in
cell subsets for any of the markers chosen occurred in the first
couple of weeks following inoculation in group B, making it un-
likely that the changes observed conferred protection from infec-
tion.
In summary, once initial infection is apparently cleared, pro-
tective immunity develops against repeat M. haemofelis infection.
Following naive infection, the immune response appears skewed
toward a Th1 response. Although the mechanism of this protec-
tive immunity could not be defined in the present study, an early
increase in proinflammatory cytokines does indicate their poten-
tial role. It is possible that other immunological parameters that
constitute protection were missing from this experiment; how-
ever, this opens up the opportunity for further analysis of the cats
protected from M. haemofelis by analysis of other parameters,
such as T regulatory cells, Th17 responses, and other antigens.
Despite a strong humoral response against rDnaK following naive
infection, this does not appear to be important in protective im-
munity against M. haemofelis.
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